Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daptomycin dose-effect relationship against resistant gram-positive organisms.

Raymond Cha1, Richard G Grucz, Michael J Rybak

  • 1Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 48201, USA.

Antimicrobial Agents and Chemotherapy
|April 24, 2003
PubMed
Summary

This study determined optimal daptomycin dosing for resistant bacteria. Doses between 3 and 7 mg/kg effectively reduced bacterial populations, guiding treatment for challenging gram-positive infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of colistin minimum inhibitory concentration on clinical failure and mortality: insights from the OVERCOME trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2026
Same author

Beyond traditional tetracyclines: a real-world evaluation of effectiveness and safety of omadacycline therapy for complex bacterial infections.

BMC infectious diseases·2026
Same author

Ceftazidime-avibactam for multidrug-resistant gram-negative infections: outcomes and timing of initiation across 22 U.S. medical centers.

Antimicrobial agents and chemotherapy·2026
Same author

Real-world use of eravacycline for the treatment of mono- and polymicrobial infections involving Enterobacterales.

Microbiology spectrum·2026
Same author

Clinical Pharmacology Quality Assurance Program for Global HIV and Co-Infection Drug Development.

Clinical pharmacology and therapeutics·2026
Same author

Optimizing discharge antibiotic prescribing: A multicenter evaluation of pharmacist-led interventions in community hospitals.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Daptomycin is a key antibiotic for Gram-positive bacterial infections.
  • Rising antimicrobial resistance necessitates optimized dosing strategies.
  • Understanding daptomycin's pharmacodynamics against resistant strains is crucial.

Purpose of the Study:

  • To establish a once-daily daptomycin dosing regimen using pharmacodynamic modeling.
  • To correlate dosing with specific pharmacodynamic endpoints for resistant Gram-positive bacteria.
  • To evaluate daptomycin efficacy against methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-intermediate resistant S. aureus (GISA), and vancomycin-resistant Enterococcus faecium (VREF).

Main Methods:

  • An in vitro pharmacodynamic model simulated daptomycin doses from 0-9 mg/kg/day.

Related Experiment Videos

  • Bacterial density was monitored over 48 hours for MRSA, GISA, and VREF isolates.
  • Sigmoid dose-response models estimated effective doses for 50% (ED(50)) and 80% (ED(80)) bacterial reduction.

    • Main Results:

    • Daptomycin MICs varied from 0.125 to 4 µg/ml.
    • ED(50) and ED(80) values differed significantly across resistant species, ranging from 1.9/3.1 mg/kg for MRSA to 5.4/6.8 mg/kg for VREF.
    • Doses of 3-7 mg/kg demonstrated significant bactericidal activity (ED(80)) against these multidrug-resistant strains.

    Conclusions:

    • Daptomycin dosing requirements vary based on the specific resistant Gram-positive pathogen.
    • Pharmacodynamic modeling provides a framework for optimizing daptomycin regimens against resistant infections.
    • The study supports the use of 3-7 mg/kg daptomycin for treating infections caused by MRSA, GISA, and VREF.